Biological PsychiatryMarch 8, 2025Jonathan Repple, Maximilian Bayas, Chiara Möser et al.8 citations
After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, particularly rapid-acting antidepressants (RAADs). Despite these promising developments, there remains a significant gap in research on bipolar depression. While several antipsychotics have been investigated for their efficacy in bipolar depression...
A 1-year-old, male entire English Springer Spaniel dog, presented for computed tomography investigation of bilateral pelvic limb gait abnormality. The dog developed tension pneumothorax shortly after intubation because of erroneous connection of the endotracheal tube to the auxiliary oxygen flowmeter instead of the breathing circuit. A prompt diagnosis, based on reduced compliance during manual...
Depression in older adults is often undertreated. A 2011 systematic review of treatments for treatment-resistant depression (TRD) in older adults identified one placebo-controlled randomised controlled trial (RCT). We aimed to update this review, synthesising evidence for the effectiveness of treatments for TRD in older people. We systematically searched electronic databases (PubMed, Cochrane,...
Little is known about ecstasy/MDMA use among Asian American and Pacific Islander populations. Research is important because AAPIs face unique cultural factors that may influence use. We estimated the prevalence and correlates of lifetime ecstasy/MDMA use based on a representative sample of US AAPI adults aged ≥18 from the 2015-2020 National Survey on Drug Use and Health. An estimated 5.1% of...
Novel antidepressive substances are challenging the explanations for the mechanisms of action of traditional psychopharmacology. What could be the shared effects of various antidepressants and in this context what role do extrapharmacological factors, such as the body and environment, play? The available literature on clinical and preclinical data for assumed combined active factors of...
Surgical procedures induce stress responses similar to severe illnesses, activating the metabolic and neuroendocrine systems, especially the hypothalamic-pituitary-adrenal (HPA) axis. The resulting cortisol surge maintains homeostasis but can adversely affect recovery by elevating blood glucose levels and increasing the risk of complications. Given the high prevalence of opium use, especially...
The Hallucinogen Rating Scale (HRS) has been widely used to measure the subjective effects of psychedelics and other psychoactive substances. Its advantages include a basis in phenomenological interviews and clinical studies, straightforward items, and broad coverage of psychedelic effects. Previous studies have attempted to resolve its factor structure but were limited by small samples of...
Abstract Anhedonia is a transdiagnostic domain that leads to poor disorder outcome and low remission rates. This narrative review describes a broad range of interventions targeting anhedonia, including pharmacological, neuromodulatory, behavioral, and lifestyle‐based approaches. Drugs such as vortioxetine, agomelatine, bupropion, ketamine, and brexpiprazole show promising anti‐anhedonic...
Psychedelic-assisted therapy (PAT) is an emerging treatment approach that often combines pharmacotherapeutic dosing sessions with more traditional psychotherapy. Despite limited formal regulatory approval, treatment seekers can currently access PAT through a variety of avenues, including ketamine treatment centers and “supported adult use” psilocybin centers in the U.S., drug tourism,...
Hallucinogenic substances such as psilocybin, LSD or ecstasy are now the subject of several hundred clinical trials around the world to test their ability to restore our mental health. Psilocybin (active ingredient in hallucinogenic mushrooms), LSD (derived from compounds from ergot), dimethyltryptamine (or DMT, part of the composition of ayahuasca), mescaline (derived from peyote), but also...